Pharmacist-Led GLP-1 Weight Management in Cardiology Patients Achieves 12.6% Weight Loss
All 31 cardiology patients who completed 6 months of pharmacist-managed GLP-1 receptor agonist treatment achieved at least 5% weight loss, with an average of 12.6% plus improvements in cholesterol, blood sugar, and blood pressure.
Quick Facts
What This Study Found
100% of 31 completers achieved ≥5% weight loss at 6 months, with mean weight loss of 12.6%. Cardiometabolic markers also improved: HbA1c -0.6%, LDL -18 mg/dL, triglycerides -29 mg/dL, systolic BP -9 mmHg.
Key Numbers
The study evaluated outcomes from a pharmacist-managed service using GLP-1 RAs in a cardiology clinic population.
How They Did This
Single-center, prospective, pre-post analysis of adults with BMI ≥30 (or ≥27 with comorbidity) managed by a clinical pharmacist using GLP-1 RAs (semaglutide or liraglutide) with lifestyle counseling in a cardiology clinic, March 2022 to March 2023.
Why This Research Matters
Cardiology patients with obesity face compounded cardiovascular risk. This study shows that pharmacist-led GLP-1 management can deliver meaningful weight loss plus improvements in multiple cardiac risk factors — a model that could expand access to these treatments.
The Bigger Picture
With GLP-1 drug demand outstripping physician capacity, pharmacist-led management models could help close the treatment gap. This cardiology clinic model demonstrates that pharmacists can effectively manage the complex dose titration and insurance challenges of GLP-1 therapy while achieving excellent clinical outcomes.
What This Study Doesn't Tell Us
No control group — cannot separate drug effects from pharmacist intervention and lifestyle changes. High dropout: only 31 of 59 starters completed 6 months. Single-center study. Selection bias from insurance coverage requirement (only patients with coverage for Wegovy/Saxenda).
Questions This Raises
- ?Why did nearly half of patients not complete 6 months, and could pharmacist intervention reduce dropout?
- ?Would a randomized trial comparing pharmacist-led versus physician-led GLP-1 management show similar outcomes?
- ?Can this pharmacist-led model scale to primary care settings where most obesity patients are treated?
Trust & Context
- Key Stat:
- 12.6% mean weight loss All 31 completers in a pharmacist-led cardiology weight clinic achieved this with GLP-1 drugs plus lifestyle counseling
- Evidence Grade:
- Moderate evidence — prospective pre-post study with no control group. Strong outcomes but selection bias and high dropout limit generalizability.
- Study Age:
- Published in 2024 with data from March 2022-2023, reflecting current GLP-1 prescribing practices.
- Original Title:
- Reprint of: Impact of a pharmacist-led weight management service in a cardiology clinic.
- Published In:
- Journal of the American Pharmacists Association : JAPhA, 64(4S), 102157 (2024)
- Authors:
- Yates, Madison, Supple, Megan, Maccia, Melissa
- Database ID:
- RPEP-09601
Evidence Hierarchy
Frequently Asked Questions
Why would a pharmacist manage weight loss drugs instead of a doctor?
GLP-1 drugs require frequent dose adjustments, patient education about injection technique, and complex insurance navigation. Pharmacists are specifically trained for these tasks and can free up physician time while providing more accessible care through collaborative practice agreements.
Did the weight loss also improve heart health markers?
Yes — beyond the 12.6% average weight loss, patients saw improvements in LDL cholesterol (-18 mg/dL), triglycerides (-29 mg/dL), blood sugar (HbA1c -0.6%), and systolic blood pressure (-9 mmHg), all of which reduce cardiovascular risk.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09601APA
Yates, Madison; Supple, Megan; Maccia, Melissa. (2024). Reprint of: Impact of a pharmacist-led weight management service in a cardiology clinic.. Journal of the American Pharmacists Association : JAPhA, 64(4S), 102157. https://doi.org/10.1016/j.japh.2024.102157
MLA
Yates, Madison, et al. "Reprint of: Impact of a pharmacist-led weight management service in a cardiology clinic.." Journal of the American Pharmacists Association : JAPhA, 2024. https://doi.org/10.1016/j.japh.2024.102157
RethinkPeptides
RethinkPeptides Research Database. "Reprint of: Impact of a pharmacist-led weight management ser..." RPEP-09601. Retrieved from https://rethinkpeptides.com/research/yates-2024-reprint-of-impact-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.